Gilead Sciences (GILD) Has Hidden NASH Value - Gabelli

September 22, 2016 3:43 PM EDT
Get Alerts GILD Hot Sheet
Price: $71.93 +0.03%

Rating Summary:
    24 Buy, 11 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 11 | Down: 22 | New: 54
Trade GILD Now!
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

While Gilead Sciences (NASDAQ: GILD) is modestly lower Thursday following the suspension of its phase 2/3 for GS-5745, Gabelli analyst Jing He is highlighting the company's hidden value in NASH.

He sees the NASH market at $20 billion by 2025 and notes Gilead has the most comprehensive NASH portfolio with four NASH candidates.

Gilead is expecting two Phase II readouts from simtuzumab and GS-4997 (ASK-1 inhibitor) in 2H’16.

The analyst sees GILD as having a compelling valuation. "We are reiterating our Buy recommendation on Gilead. Its NASH portfolio is a hidden asset behind Hep C and HIV, with multiple readouts expected in 2H’16. We see increasing value in this franchise and believe Gilead will become a leader in NASH."

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Corporate News

Add Your Comment